Guiding Values

Improve the quality of life for all members of the heart failure care community,
including patients, caregivers and clinicians.

Enable proactive heart failure management by providing data-driven patient management
solutions that detect worsening heart failure early and help inform ongoing therapeutic interventions.

Create practice EFficiencies by streamlining patient management, clinical data organization,
communication, coordination, and reimbursement in one comprehensive solution.

Our Story
Milestones

Anthony Nunez, MD, a cardiothoracic surgeon, and Harry Rowland, PhD, a mechanical engineer, are the co-founders of Endotronix. They were inspired to start the company because they witnessed family members suffering from heart failure (HF). They realized they were uniquely qualified to invent a more effective solution to improve the quality of life for HF sufferers, their loved ones and caregivers treating the disease.

January 2017

First patient use of the myCordella™ system as part of the clinical development program

January 2017

Expanded funding with $12M in debt financing from Silicon Valley Bank

December 2016

Introduced the CordellaTM Heart Failure System, a comprehensive solution for heart failure management

July 2016

Closed a $32M Series C Financing round with a world class investor group to support clinical development and commercialization activities

INVESTOR GROUP:

July 2015

Completed a comprehensive in-vivo study of the 1st generation sensor system

November 2014

Named a Distinguished Award winner in the Nokia Sensing XCHALLENGE, a worldwide competition identifying the most innovative technology

February 2014

Demonstrated an enhanced catheter-based delivery system that allowed for improved clinician control and visualization during sensor implantation for the first time in vivo

October 2013

Established corporate headquarters in Chicago, IL

April 2013

Received a U.S. patent for its breakthrough wireless sensor reader technology

March 2013

Developed a novel sensor platform for implantable wireless electronics

November 2012

Demonstrated proof-of-concept for the catheter-based delivery system in an acute in-vivo model

January 2011

Built a prototype reader the size of a smart phone, showing the potential for patient friendly readings from the implantable pressure sensor

October 2010

The Central Illinois Angels from Peoria, IL and JumpStart Ventures from Cleveland, OH became investors

November 2009

Accomplished the first in vivo demonstration of its wireless sensor reader technology at Cleveland Clinic’s Lerner Research Institute

February 2009

Received a $3 million investment from Luxemburg Capital, founded by successful healthcare entrepreneur James Hummer, to expand development efforts

July 2008

Completed licensing for two patents from NASA for ultra-miniature wireless sensor designs

February 2008

Worked with collaborators formerly of Bradley University and Caterpillar to make a breakthrough innovation, a new technology that passively reads wireless sensors

June 2007

Anthony and Harry founded Endotronix

February 2007

Anthony and Harry met in Peoria, Illinois

Management Team
Management Team

Harry D. Rowland, PhD

Dr. Rowland has led the company’s operations, strategy, and technology development since inception. He received his PhD in mechanical engineering from the Georgia Institute of Technology as well as a BS in mechanical engineering and MA in economics from the University of California, Santa Barbara. Dr. Rowland’s professional interests are at the intersection of transformative technologies and emerging business opportunities. He has been active in research and development of micro and nanotechnology fabrication methods for 15 years, including invited research at Sandia National Laboratories, New Mexico and Trinity College, Ireland. Dr. Rowland has authored or presented over 15 conference and journal papers in internationally recognized peer-reviewed publications such as Science and Nano, with his work referenced in more than 300 scholarly articles. He is an inventor on 10 issued patents and several pending applications.

Katrin Leadley, MD

Dr. Leadley is a seasoned clinical executive bringing medical and scientific expertise to Endotronix. Before joining Endotronix, Dr. Leadley was the Chief Medical Officer at HeartWare (acquired by Medtronic in 2016) where she was responsible for all medical, clinical and regulatory affairs, including the design and execution of HeartWare’s clinical trial program. Prior to HeartWare, Dr. Leadley served as the Chief Medical Officer at JenaValve Technology. She has also held a variety of leadership positions in Clinical Services at Boston Scientific Corporation with increasing responsibility. Prior to Boston Scientific, Dr. Leadley held managerial positions at several other life sciences companies, including Advanced Stent Technologies, Pulmonx and Quintiles/The Lewin Group in San Francisco. She has authored numerous scientific and medical publications and presented at industry conferences and events around the world.

Dr. Leadley earned her medical degree at Ludwig-Maximillian University Medical School in Munich. She was also awarded a National Institute of Health Postdoctoral Fellowship by the School of Public Health at the University of California at Berkeley.

Michael L. Nagy

Michael Nagy has led Endotronix’s engineering and product development efforts since 2009. Mr. Nagy has 25 years of experience leading advanced engineering teams at Olympus, Goodrich, the European Space Agency, and several successful start-ups, where he developed, qualified, and commercialized breakthrough microelectronics and MEMS products for aerospace, consumer, telecommunications, and biomedical applications. Mr. Nagy holds bachelor’s and master’s degrees in electrical engineering from the University of Detroit and Case Western Reserve University, respectively. He is an inventor on more than a dozen patents for MEMS-based products.

Richard Powers

Mr. Powers is a seasoned senior healthcare executive with extensive experience in early stage companies. Most recently he was the Chief Technology Officer at WebOps, a company that offers Software-as-a-Service (SaaS) logistics tracking for the medical device industry. Prior to WebOps, Mr. Powers had an impressive tenure at CardioMEMS, Inc, culminating as Chief Information Officer. He created a ground-breaking secure cloud-based SaaS disease management platform that was a key value driver for the 2014 acquisition by St. Jude Medical valued at over $475 million. After the acquisition, Mr. Powers was responsible for integration of the system into the St. Jude Medical platform. His experience includes sensor engineering, software design and development, clinical, marketing, and information systems. Prior to CardioMEMS, Mr. Powers was employed in the telecommunications industry at CIENA Corporation, ARRIS Network Technologies, and CISCO (formerly Scientific Atlanta).

Mr. Powers is a member of the Board of Advisors for the Health Society of the Technology Association of Georgia (TAG), a member of the Board of Directors for the Cloud Society of TAG, a member of the Board of Directors for Trinity Early Learning Center, and a finalist for the 2013 and 2014 Georgia CIO of the Year® Awards.

Mr. Powers earned bachelor’s and master’s degrees in Electrical and Computer Engineering from Georgia Institute of Technology as well as an MBA from Georgia Tech’s Scheller College of Business.

J. Kent Elmer

As managing partner of TechCXO, Kent Elmer provides CFO and related financial services to Endotronix. Mr. Elmer is a CPA with more than 20 years of broad-based experience ranging from Big 4 international public accounting to CFO-level positions at a variety of companies. He began his career at Arthur Andersen & Co. After gaining a strong foundation, he made the transition to the private sector. His public company experience includes various positions including Controller and CFO of IQ Software Corporation, a NASDAQ software company. He has also been the CFO of a number of early- and growth-stage technology ventures in both software and hardware. Every private sector company that Mr. Elmer has worked for has successfully navigated its way through the acquisition process.

Nicolas Chronos, MD

Dr. Chronos is an interventional cardiologist well known for his pioneering research in the treatment of heart disease. He is an expert in cardiac regenerative medicine, cardiovascular medical device assessment, and translational cardiovascular medicine. Dr. Chronos has extensive experience with preclinical and clinical development of a variety of medical devices.  He is a Consulting Professor of Cardiology and Medicine at Stanford University, and he continues to see patients at Cardiology Care Clinics located near Atlanta in Lake Oconee, Georgia.  Previously, Dr. Chronos was CEO of St. Joseph’s Translational Research Institute in Atlanta, Adjunct Professor at Duke University, and Adjunct Partner at Essex Woodlands Health Ventures.  His distinguished career began with a Degree in Medicine and Surgery from the Royal Free Hospital School of Medicine at the University of London.  He trained in cardiology and interventional cardiology at the Royal Brompton National Heart and Lung Institute in London. Dr. Chronos was awarded a British Heart Foundation International Fellowship and continued his research in interventional cardiology in the United States at Emory University School of Medicine.

Mike Dilworth

Mike Dilworth is a seasoned manufacturing and operations executive in the healthcare industry. Most recently, Mike was Senior VP of Manufacturing Operations at Nanosphere (acquired by Luminex Corporation in 2016). Prior to that he held VP of Manufacturing roles at Plasma Surgical, Abbott Nutrition, and Ciba Vision Corporation. Throughout his career, Mike has demonstrated leadership in building winning teams as well as formulating and executing strategic plans. He has a proven ability to increase sales and profit by working with R&D and Marketing organizations to bring new products and processes to the market.

Mike holds a Bachelor of Science degree in Industrial Management from Georgia Southern College.

Bradley C. Poff, DVM

Dr. Brad Poff is responsible for preclinical strategy, generating safety data for current clinical indications and investigating future applications of Endotronix technology. For 28 years he has led research teams in preclinical, clinical, and regulatory at both large and startup medical device companies. Dr. Poff was a co-founder and General Manager of Augmenix, Inc. where he built and led a team from company initiation to CE Mark approval of the lead product within 2 years. Prior to Augmenix, Dr. Poff was Vice President of Preclinical Sciences at Boston Scientific where his group supported all business units including cardiovascular, endosurgery, and neurosurgery. He was responsible for guiding business unit decision-making and speeding product introduction by developing sound safety data and regulatory messaging for Class 3 medical devices. Prior to Boston Scientific, Dr. Poff served in leadership roles at Genzyme, Focal, Guidant and 3M. He has authored or co-authored 52 papers and holds 8 patents. Dr. Poff holds a Doctorate in Veterinary Medicine (DVM) and BS from the University of Wisconsin.

Board of Directors
Board of Directors

Paul LaViolette

A seasoned medtech executive, Paul LaViolette has over 33 years of global medical technology management experience. Mr. LaViolette currently serves as Managing Partner and COO of SV Life Sciences (SVLS). Prior to SVLS, Mr. LaViolette served as Chief Operating Officer at Boston Scientific Corporation. During his 15 years at BSC, he held numerous senior management positions as the company grew revenues over 20 times. Mr. LaViolette integrated two dozen acquisitions and led extensive product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Covidien). Mr. LaViolette serves as Vice Chairman of the Innovation Advisory Board for the Partners Health System and is Chairman for the Medical Device Manufacturers Association. Mr. LaViolette received his BA in Psychology from Fairfield University and his MBA from Boston College.

Gerry Brunk

Gerry Brunk is a Managing Director at Lumira Capital and brings over 25 years of investment, consulting and entrepreneurial experience in the health care industry to the Endotronix Board. Prior to joining Lumira Capital in 2002, Mr. Brunk was an entrepreneur in the life sciences sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston in New York. Mr. Brunk received his BA in biology and economics from the University of Virginia and his MBA from the Stanford University Graduate School of Business. Mr. Brunk currently sits on several boards including BAROnova, Cardiac Dimensions, Celtaxsys, Corvia Medical and Southeast BIO.

Marc Goldberg

Co-founder and General Manager of BioVentures Investors, Marc Goldberg brings over 25 years of medical device and diagnostic experience to Endotronix. Previously, Mr. Goldberg served as President and CEO of the Massachusetts Biotechnology Research Institute, which raised $20 million in funding and was responsible for the launch of 24 new companies during his tenure. Earlier in his career, Mr. Goldberg held senior management roles at Safer, Inc., a developer and manufacturer of biopesticides and related products. Before Safer, he was Manager, Business Development at Genetics Institute, one of the earliest biotechnology companies. Mr. Goldberg served four terms as the President of the Massachusetts Biotechnology Council, of which he was Founding President, and as a Director from its inception in 1985 to 1997. He earned his AB from Harvard College, his JD from Harvard Law School, and his MBA from Harvard Business School. Mr. Goldberg is currently a member of the Harvard Medical School Neuroscience Advisory Committee and served as a member of the Beth Israel Deaconess Medical Center Board of Directors Research Advisory Committee.

James J. Hummer

James Hummer was the Founder and former President and CEO of Whole Health Management, a leading health services company that was acquired by Walgreen Company in 2008. He has over 30 years of experience implementing and managing ambulatory care and work-site, employer-based health services. Prior to founding Whole Health, Mr. Hummer was the co-founder of Ivy Medical Group, one of the country’s largest ambulatory care companies in the mid-1980s. Mr. Hummer received his BBA degree from the University of Notre Dame and a MBA from Harvard University. He currently serves on Harvard University’s Healthcare Initiative Advisory Board, The Harvard School of Public Health Leadership Council, and the Qualcomm Life Health Advisory Board.

Jennifer McMahon

Jennifer McMahon is an Associate at Seroba Life Sciences with over five years’ investment experience. After graduating from University College Dublin with an honours degree in Pharmacology in 2010, Jennifer entered a Master’s degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her Master’s degree in 2011, Jennifer then joined Seroba’s Investment Team as an Investment Analyst. She sits on the board of directors of Biosensia and Endotronix. Jennifer is a Dublin-hub Ambassador of the Sandbox network, a global community for ‘exceptional innovators’. In October 2015, Jennifer was recognized as one of Ireland’s ‘Top 30 Under 30’, shaping the future of business in the country. She guest-lectures on venture capital at University College Dublin, Trinity College Dublin and the Royal College of Surgeons, Ireland.

Harry D. Rowland, PhD

Dr. Rowland has led the company’s operations, strategy, and technology development since inception. He received his PhD in mechanical engineering from the Georgia Institute of Technology as well as a BS in mechanical engineering and MA in economics from the University of California, Santa Barbara. Dr. Rowland’s professional interests are at the intersection of transformative technologies and emerging business opportunities. He has been active in research and development of micro and nanotechnology fabrication methods for 15 years, including invited research at Sandia National Laboratories, New Mexico and Trinity College, Ireland. Dr. Rowland has authored or presented over 15 conference and journal papers in internationally recognized peer-reviewed publications such as Science and Nano, with his work referenced in more than 300 scholarly articles. He is an inventor on 10 issued patents and several pending applications.

Robert Zieserl

Bob Zieserl is a serial entrepreneur, venture capitalist, and angel investor with over 30 years of experience in healthcare and technology. He is currently CEO of simMachines, an advanced predictive analytics company. He previously was CEO of Vital Sensors, a cardiovascular device company.  In addition, he served as Managing Director of KB Partners venture firm and led the life science investments for the firm. Prior to KB Partners, Mr. Zieserl led Software Development Systems (SDS) to the acquisition by Intel. He formed Tomtec Imaging Systems through the merger of two companies and pioneered 3D cardiovascular ultrasound. He led Medicus Systems Corporation a leading health care IT company through a successful IPO. Mr. Zieserl received his MS from Loyola University Quinlan Graduate School of Business and his BA from Marquette University. He completed a post-graduate residency in Health Care Management at Rush University. Mr. Zieserl is a Charter Member of TiE Midwest, and has been a leader in both the Young Presidents Organization (YPO) and World Presidents Organization (WPO).

Careers
Join Our Team

We’re seeking dedicated individuals who are passionate about transforming heart failure with new medical, sensor and mobile technology.

Do you thrive in a startup environment? Do you want to help revolutionize the clinical practice for patients with advanced heart failure? If so, we want to hear from you.

Current Openings:

Top